-
Assisting Grieving Families to Find Closure While Maintaining Compliance with HIPAA
The most fundamental goals of Harm Reduction and Buprenorphine Programs are to keep people alive and safe. Despite the best efforts of a very dedicated SUD workforce, over 107,000 people died of overdose deaths in 2023. Behind every overdose death is a family or friends in mourning. Often, they are...
-
Only 1 in 4 Adolescent Treatment Facilities Offer Buprenorphine for Opioid Use Disorder
Only 1 in 4 residential addiction treatment facilities caring for U.S. adolescents under 18 years old offer buprenorphine, a medication used to treat opioid use disorder, according to a new study. Only 1 in 8 offer buprenorphine for ongoing treatment. These findings highlight a significant gap in...
-
Buprenorphine Initiation in the ER Found Safe and Effective for Individuals With Opioid Use Disorder Who Use Fentanyl
Results from a multi-site clinical trial supported by the National Institutes of Health showed that less than 1% of people with opioid use disorder whose drug use includes fentanyl experienced withdrawal when starting buprenorphine in the ER. The findings, which appeared today in JAMA Network Open,...
-
Overdose Deaths Involving Buprenorphine Did Not Proportionally Increase With New Flexibilities in Prescribing
The proportion of opioid overdose deaths involving buprenorphine, a medication used to treat opioid use disorder, did not increase in the months after prescribing flexibilities were put in place during the COVID-19 pandemic, according to a new study. These data provide evidence that may help to...
-
NIH Research Matters – Telehealth Improves Treatment for Opioid Use Disorder
Telehealth improves treatment for opioid use disorder for people during the COVID-19 pandemic, increasing the likelihood of staying on their medications and less likely to overdose. The findings support continuing the expanded telehealth access that began during the pandemic. Medications...
-
Behavioral Health News Spotlight on Excellence: An Interview with Mary Brewster, Associate Commissioner for Harm Reduction at the New York State Office of Addiction Services and Supports (OASAS)
Overview David Minot, Executive Director of Mental Health News Education, the non-profit organization that publishes Behavioral Health News, interviewed Mary Brewster, Associate Commissioner for Harm Reduction at the New York State Office of Addiction Services and Supports (OASAS). The mission of...
-
Offering Buprenorphine Medication to People with Opioid Use Disorder in Jail May Reduce Rearrest and Reconviction
A study conducted in two rural Massachusetts jails found that people with opioid use disorder who were incarcerated and received a medication approved to treat opioid use disorder, known as buprenorphine, were less likely to face rearrest and reconviction after release than those who did not...
-
Buprenorphine Misuse Decreased Among U.S. Adults with Opioid Use Disorder From 2015-2019
Data from a nationally representative survey indicate that in 2019, nearly three-fourths of U.S. adults reporting buprenorphine use did not misuse the medication in the past 12 months. In addition, buprenorphine misuse among people with opioid use disorder trended downward between 2015-2019,...
